

## 4DMedical™ Expands into Europe with Acquisition of AI Lung Imaging Leader contextflow

---

NEWS PROVIDED BY  
4DMedical  
JUN 1, 2026, 08:20 ET

---

MELBOURNE, Australia, June 1, 2026– 4DMedical Limited (ASX: 4DX), a global leader in advanced respiratory imaging, today announced a major expansion into Europe through signing a binding agreement to acquire **contextflow GmbH**, an Austria-based category leader in AI-driven lung cancer detection and radiology workflow solutions.

The transaction provides 4DMedical with an **immediate, on-the-ground European comprehensive commercial platform**, significantly accelerating its global growth strategy and establishing operations across North America, Europe and Australia.

### Integrating AI and Functional Lung Imaging

While the transaction is strategically focused on geographic expansion, it also enhances 4DMedical's technology platform.

contextflow's AI-based detection and workflow tools, particularly in lung cancer screening, complement 4DMedical's functional imaging capabilities, which enable quantitative assessment of ventilation, perfusion and lung mechanics.

Together, the combined portfolio supports a more complete clinical pathway:

- **Detection and triage** of lung abnormalities
- **Diagnostic assessment** using functional imaging
- **Monitoring and disease progression tracking**

This integrated offering positions 4DMedical as a differentiated provider of both **structural and functional lung insights** for radiology and respiratory care.

### Strategic European Market Entry

Europe represents a critical growth market for advanced imaging, lung cancer screening and AI-enabled clinical decision support. Through the acquisition of contextflow, 4DMedical gains:

- A **European-based team with established commercial and technical expertise**
- An existing **customer base and clinical footprint across Europe**
- A **CE-marked product suite already deployed in routine clinical workflows**
- A regulatory platform aligned with **Europe's Medical Device Regulation (MDR)**

This foundation enables 4DMedical to bypass the time and complexity of establishing a new regional presence, creating an immediate pathway to revenue and scale.

### Accelerating Commercialisation and Cross-Selling

The European footprint creates near-term opportunities to expand adoption of 4DMedical's broader portfolio, including its functional lung imaging technologies.

By combining complementary product suites, the company is positioned to:

- Introduce **functional lung imaging solutions** into established European radiology workflows
- Cross-sell into an existing installed base of customers
- Expand into markets with **established reimbursement pathways**, including Germany
- Accelerate time to market for new AI-enabled solutions

The addition of a commercially active, MDR-compliant platform further reduces regulatory friction and enables scalable growth across multiple European markets.

### Strengthening a Transatlantic Clinical Network

The expansion significantly enhances 4DMedical's engagement with **key opinion leaders (KOLs)** across Europe, strengthening its global clinical network.

Combined with existing relationships in the United States, this creates a **transatlantic ecosystem** that supports:

- Faster clinical validation and real-world evidence generation
- Greater alignment with international diagnostic standards
- Expanded collaboration with pharmaceutical and biotechnology partners running multinational trials

This broader network is expected to accelerate adoption of advanced lung imaging technologies and support future product development.

### Leadership and Regional Growth

As part of the expansion, continuity of leadership and regional expertise will be maintained.

Markus Holzer, CEO of contextflow, will assume the role of **General Manager of 4DMedical Europe**, leading the company's growth across the region and reporting to Founder and CEO Andreas Fouras.

### Positioned for Global Scale

With an operational footprint now spanning three continents, 4DMedical is securing its goal of becoming the **global leader in advanced lung analysis software**.

The European expansion strengthens the company's ability to:

- Scale commercial operations internationally
- Access large and diverse patient populations
- Accelerate innovation in AI-driven imaging
- Build long-term strategic partnerships across healthcare and industry

By combining geographic expansion with complementary technology, 4DMedical is well positioned to play a leading role in advancing lung disease detection, diagnosis and management worldwide.



## About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**<sup>®</sup> transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS**<sup>®</sup>), **CT LVAS**<sup>™</sup>, and the ground-breaking **CT:VQ**<sup>™</sup> solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at [www.4dmedical.com](http://www.4dmedical.com)

## About contextflow

contextflow is a Vienna-based medical imaging AI company developing clinical decision support software to enhance the detection and management of lung diseases, including lung cancer, interstitial lung disease (ILD) and COPD. Founded in July 2016 as a spin-off from the Medical University of Vienna and the Khresmoi European research project, and supported by the Technical University of Vienna, the company has developed proprietary AI solutions for the analysis of chest CT scans, including its CE-marked **ADVANCE Chest CT** product. contextflow's technology is designed to improve diagnostic accuracy and workflow efficiency for radiologists, while supporting healthcare providers, pharmaceutical companies and payers.

The company has gained international recognition for its innovation and commercial progress, including selection for the Philips HealthWorks accelerator program and multiple industry awards. contextflow has also received grant and investment funding from the European Innovation Council and has secured a pioneering reimbursement agreement for lung cancer screening in Germany, with first revenues received in Q3 2025, marking a key step toward broader adoption of reimbursed AI-driven screening solutions in Europe.

Learn more at [www.contextflow.com](http://www.contextflow.com)